ACOG practice bulletin number 67: Medical management of abortion

Obstetrics and Gynecology

Volumn 106, Issue 4, 2005, Pages 871-881

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; CHORIONIC GONADOTROPIN BETA SUBUNIT; IBUPROFEN; METHOTREXATE; MIFEPRISTONE; MISOPROSTOL; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RHESUS D ANTIBODY; TAMOXIFEN;

ABDOMINAL CRAMP; ANTIBIOTIC PROPHYLAXIS; BREAST CANCER; CAUSE OF DEATH; CHILL; CLINICAL TRIAL; CURETTAGE; CUSHING SYNDROME; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELF ADMINISTRATION; ENDOMETRIOSIS; FATIGUE; FEMALE INFERTILITY; GASTROINTESTINAL SYMPTOM; GESTATIONAL AGE; GLAUCOMA; HEADACHE; HEAT SENSATION; HUMAN; INFECTION RISK; LABORATORY TEST; MOUTH ULCER; NAUSEA; PAIN; PATIENT COUNSELING; PREGNANCY RATE; PREGNANCY TERMINATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TERATOGENICITY; THERAPEUTIC ABORTION; THERMOREGULATION; TRANSVAGINAL ECHOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; UNITED STATES; UTERUS CONTRACTILITY; UTERUS MYOMA; VAGINA BLEEDING;

ABORTIFACIENT AGENTS; ABORTION, INDUCED; DILATATION AND CURETTAGE; DIRECTIVE COUNSELING; FEMALE; HUMANS; PREGNANCY; UNITED STATES;

EID: 25444449873     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Finer LB, Henshaw SK. Abortion incidence and services in the United States in 2000. Perspect Sex Reprod Health 2003;35:6-15. (Level II-3)
2. Gravanis A, Schaison G, George M, de Brux J, Satyaswaroop PG, Baulieu EE, et al. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J Clin Endocrinol Metab 1985;60:156-63. (Level II-3)
3. Johannisson E, Oberholzer M, Swahn ML, Bygdeman M. Vascular changes in the human endometrium following the administration of the progesterone antagonist RU 486. Contraception 1989:39;103-17. (Level II-2)
4. Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol 1988;95:126-34. (Level II-2)
5. Danielsson KG, Marions L, Rodriguez A, Spur BW, Wong PY, Bygdeman M. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol 1999;93:275-80. (Level II-2)
6. Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997;90:88-92. (Level II-1)
7. Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception 2005;71:22-5. (Level II-3)
8. Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002;17:332-6. (Level I)
9. Wiebe ER. Tamoxifen compared to methotrexate when used with misoprostol for abortion. Contraception 1999;59:265-70. (Level I)
10. Jain JK, Meckstroth KR, Park M, Mishell DR Jr. A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception 2000;60:353-6. (Level I)
11. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241-7. (Level II-3)
12. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. BJOG 2000;107:524-30. (Level I)
13. Aubény E, Peyron R, Turpin CL, Renault M, Targosz V, Silvestre L, et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [published erratum appears in Int J Fertil Menopausal Stud 1996;41:56]. Int J Fertil Menopausal Stud 1995;40 (suppl 2):85-91. (Level II-3)
14. Creinin MD, Spitz IM. Use of various ultrasound criteria to evaluate the efficacy of mifepristone and misoprostol for medical abortion. Am J Obstet Gynecol 1999;181:1419-24. (Level II-3)
15. McKinley C, Thong KJ, Baird DT. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod 1993;8:1502-5. (Level I)
16. el-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995;332:983-7. (Level I)
17. Honkanen H, Piaggio G, Hertzen H, Bartfai G, Erdenetungalag R, Gemzell-Danielsson K, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. WHO Research Group on Post-Ovulatory Methods for Fertility Regulation. BJOG 2004;111:715-25. (Level I)
18. Schaff EA, Fielding SL, Eisinger SH, Stadalius LS, Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception 2000;61:41-6. (Level II-3)
19. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy [published erratum appears in Contraception 2002;66:481]. Contraception 2002;66:247-50. (Level I)
20. von Hertzen H, Honkanen H, Piaggio G, Bartfai G, Erdenetungalag R, Gemzell-Danielsson K, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy. WHO Research Group on Post-Ovulatory Methods for Fertility Regulation. BJOG 2003;110:808-18. (Level I)
21. Schaff EA, Stadalius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. J Fam Pract 1997;44:353-60. (Level II-3)
22. Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception 1999;59:1-6. (Level II-3)
23. Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadalius LS, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial [published erratum appears in JAMA 2000;284:2597]. JAMA 2000;284:1948-53. (Level I)
24. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception 2001;64:81-5. (Level I)
25. Wiebe E, Dunn S, Guilbert E, Jacot F, Lugtig L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet Gynecol 2002;99:813-9. (Level I)
26. Creinin MD, Potter C, Holovanisin M, Janczukiewicz L, Pymar HC, Schwartz JL, et al. Mifepristone and misoprostol and methotrexate/misoprostol in clinical practice for abortion. Am J Obstet Gynecol 2003;188:664-9. (Level II-3)
27. Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. MOD Study Trial Group. Obstet Gynecol 2004;103:851-9. (Level I)
28. Creinin MD, Vittinghoff E, Keder L, Darney PD, Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Contraception 1996;53:321-7. (Level II-3)
29. Creinin MD, Vittinghoff E, Schaff E, Klaisle C, Darney PD, Dean C. Medical abortion with oral methotrexate and vaginal misoprostol. Obstet Gynecol 1997;90:611-6. (Level II-3)
30. Creinin MD, Carbonell JL, Schwartz JL, Varela L, Tanda R. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception 1999;59:11-6. (Level I)
31. Lipscomb GH, Bran D, McCord ML, Portera JC, Ling FW. Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate. Am J Obstet Gynecol 1998;178:1354-8. (Level II-3)
32. Carbonell JL, Varela L, Velazco A, Cabezas E, Fernandez C, Sanchez C. Oral methotrexate and vaginal misoprostol for early abortion. Contraception 1998;57:83-8. (Level I)
33. Creinin MD. Oral methotrexate and vaginal misoprostol for early abortion. Contraception 1996;54:15-8. (Level I)
34. Carbonell JL, Varela L, Velazco A, Fernandez C. The use of misoprostol for termination of early pregnancy. Contraception 1997;55:165-8. (Level II-3)
35. Carbonell JL, Varela L, Velazco A, Fernandez C, Sanchez C. The use of misoprostol for abortion at ≤9 weeks' gestation. Eur J Contracept Reprod Health Care 1997;2: 181-5. (Level II-3)
36. Esteve JL, Varela L, Velazco A, Tanda R, Cabezas E, Sanchez C. Early abortion with 800 mierograms of misoprostol by the vaginal route. Contraception 1999;59:219-25. (Level II-3)
37. Jain JK, Meckstroth KR, Mishell DR Jr. Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol. Am J Obstet Gynecol 1999;181:1386-91. (Level II-2)
38. Singh K, Fong YF, Dong F. A viable alternative to surgical vacuum aspiration: repeated doses of intravaginal misoprostol over 9 hours for medical termination of pregnancies up to eight weeks. BJOG 2003;110:175-80. (Level II-3)
39. Bugalho A, Faundes A, Jamisse L, Usfa M, Maria E, Bique C. Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion. Contraception 1996;53:244-6. (Level II-1)
40. Creinin MD, Vittinghoff E. Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial. JAMA 1994;272:1190-5. (Level I)
41. Koopersmith TB, Mishell DR Jr. The use of misoprostol for termination of early pregnancy. Contraception 1996;53:238-42. (Level I)
42. Tang OS, Miao BY, Lee SW, Ho PC. Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: efficacy and acceptability. Hum Reprod 2002;17:654-8. (Level II-3)
43. Jain JK, Dutton C, Harwood B, Meckstroth KR, Mishell DR Jr. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod 2002;17: 1477-82. (Level I)
44. Creinin MD. Randomized comparison of efficacy, acceptability and cost of medical versus surgical abortion. Contraception 2000;62:117-24. (Level I)
45. Henshaw RC, Naji SA, Russell IT, Templeton AA. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. BMJ 1993;307:714-7. (Level II-1)
46. Creinin MD, Aubény E. Medical abortion in early pregnancy. In: Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG, editors. A clinician's guide to medical and surgical abortion. New York (NY): Churchill Livingstone; 1999. p. 91-106. (Level III)
47. Creinin MD, Vittinghoff E, Galbraith S, Klaisle C. A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. Am J Obstet Gynecol 1995;173:1578-84. (Level I)
48. Creinin MD. Medical abortion with methotrexate 75 mg intramuscularly and vaginal misoprostol. Contraception 1997;56:367-71. (Level II-3)
49. Creinin MD, Darney PD. Methotrexate and misoprostol for early abortion [published erratum appears in Contraception 1994;49:99], Contraception 1993;48:339-48. (Level II-3)
50. Creinin MD. Methotrexate for abortion at ≤42 days gestation. Contraception 1993;48:519-25. (Level II-3)
51. Harwood B, Meckstroth KR, Mishell DR, Jain JK. Serum beta-human chorionic gonadotropin levels and endometrial thickness after medical abortion. Contraception 2001;63:255-6. (Level III)
52. Allen RH, Westhoff C, De Nonno L, Fielding SL, Schaff EA. Curettage after mifepristone-induced abortion: frequency, timing, and indications. Obstet Gynecol 2001;98:101-6. (Level II-3)
53. Ashok PW, Penney GC, Flett GM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod 1998;13:2962-5. (Level II-3)
54. Winikoff B, Sivin I, Coyaji KJ, Cabezas E, Xiao B, Gu S, et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion. Am J Obstet Gynecol 1997;176:431-7. (Level II-3)
55. Bartley J, Brown A, Elton R, Baird DT. Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. Hum Reprod 2001;16:2098-102. (Level I)
56. Silvestre L, Dubois C, Renault M, Rezvani Y, Baulieu EE, Ulmann A. Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. A large-scale French experience. N Engl J Med 1990;322:645-8. (Level II-3)
57. Ulmann A, Silvestre L, Chemama L, Rezvani Y, Renault M, Aguillaume CJ, et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Study in 16,369 women. Acta Obstet Gynecol Scand 1992;71:278-83. (Level II-3)
58. Centers for Disease Control and Prevention. Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol-United States and Canada, 2001-2005. MMWR Morb Mortal Wkly Rep 2005;54:724.
59. Grimes DA. Risk of mifepristone abortion in context. Contraception 2005;71:161.
60. Ellertson C, Elul B, Ambardekar S, Wood L, Carroll J, Coyaji K. Accuracy of assessment of pregnancy duration by women seeking early abortions. Lancet 2000;355:877-81. (Level III)
61. Creinin MD, Jerald H. Success rates and estimation of gestational age for medical abortion vary with transvaginal ultrasonographic criteria. Am J Obstet Gynecol 1999;180:35-41. (Level 11-3)
62. Ectopic pregnancy-United States, 1988-1989. MMWR Morb Mortal Wkly Rep 1992;41:591-4. (Level II-3)
63. Van Den Eeden SK, Shan J, Bruce C, Glasser M. Ectopic pregnancy rate and treatment utilization in a large managed care organization. Obstet Gynecol 2005;105: 1052-7. (Level II-3)
64. Edwards J, Creinin MD. Surgical abortion for gestations of less than 6 weeks. Curr Probl Obstet Gynecol Fertil 1997;20:11-9. (Level II-3)
65. Paul M, Schaff E, Nichols M. The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice. Am J Obstet Gynecol 2000;183(suppl 2):S34-43. (Level III)
66. Fielding SL, Schaff EA, Nam NY. Clinicians' perception of sonogram indication for mifepristone abortion up to 63 days. Contraception 2002;66:27-31. (Level III)
67. Schaff EA, Eisinger SH, Franks P, Kim SS. Combined methotrexate and misoprostol for early induced abortion. Arch Fam Med 1995;4:774-9. (Level II-3)
68. Rossi B, Creinin MD, Meyn LA. Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. Contraception 2004;70:313-7. (Level 11-3)
69. Creinin MD, Shulman T. Effect of non-steroidal anti-inflammatory drugs on the action of misoprostol in a regimen for early abortion. Contraception 1997;56:165-8. (Level II-2)
70. Darab DJ, Minkoff R, Sciote J, Sulik KK. Pathogenesis of median facial clefts in mice treated with methotrexate. Teratology 1987;36:77-86. (Level III)
71. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990;88:589-92. (Level III)
72. Yip SK, Tse AO, Haines CJ, Chung TK. Misoprostol's effect on uterine arterial blood flow and fetal heart rate in early pregnancy. Obstet Gynecol 2000;95:232-5. (Level II-3)
73. Fonseca W, Alencar AJ, Mota FS, Coelho HL. Misoprostol and congenital malformations. Lancet 1991;338:56. (Level III)
74. Gonzalez CH, Vargas FR, Perez AB, Kim CA, Brunoni D, Marques-Dias MJ, et al. Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet 1993;47:59-64. (Level III)
75. Marques-Dias MJ, Gonzalez CH, Rosemberg S. Mobius sequence in children exposed in utero to misoprostol: neuropathological study of three cases. Birth Defects Res A Clin Mol Teratol 2003;67:1002-7. (Level III)
76. Pastuszak AL, Schuler L, Speck-Martins CE, Coelho KE, Cordello SM, Vargas F, et al. Use of misoprostol during pregnancy and Mobius' syndrome in infants. N Engl J Med 1998;338:1881-5. (Level II-2)
77. Wiebe ER. Abortion induced with methotrexate and misoprostol: a comparison of various protocols. Contraception 1997;55:159-63. (Level II-1)
78. Creinin MD. Conception rates after abortion with methotrexate and misoprostol. Int J Gynaecol Obstet 1999;65:183-8. (Level II-2)
79. Steinhoff PG, Smith RG, Palmore JA, Diamond M, Chung CS. Women who obtain repeat abortions: a study based on record linkage. Fam Plann Perspect 1979;11:30-8. (Level III)